Ingestion of aristolochic acid (AA) is associated with the development of aristolochic acid nephropathy, which is characterized by chronic renal failure, tubulointerstitial fibrosis and urothelial cancer. AA may also cause a similar type of kidney fibrosis with malignant transformation of the urothelium, the Balkan endemic nephropathy. Understanding which enzymes are involved in AA activation and/or detoxication is important in the assessment of a susceptibility to this carcinogen. The most important human enzymes activating AA by simple nitroreduction in vitro are hepatic and renal cytosolic NAD(P)H:quinone oxidoreductase, hepatic microsomal cytochrome P450 1A2 and renal microsomal NADPH:cytcohrome P450 reductase, besides cyclooxygenase, which is highly expressed in urothelial tissue. Despite extensive research, contribution of most of these enzymes to the development of these diseases is still unknown. Hepatic cytochromes P450 were found to detoxicate AA in mice, and thereby protect the kidney from injury. However, which of cytochromes P450 are the most important in this process both in animal models and in humans have not been entirely resolved as yet. In addition, the relative contribution of enzymes found to activate AA to species responsible for induction of urothelial cancer in humans remains still to be resolved.

Department of Biochemistry Faculty of Science Charles University 128 40 Prague 2 Czech Republic

Zobrazit více v PubMed

Arlt VM, Ferluga D, Stiborova M, Pfohl-Leszkowicz A, Vukelic M, Vdovic S, Schmeiser HH, Cosyns JP. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer. 2002a;101:500–502. PubMed

Arlt VM, Henderson CJ, Wolf CR, Schmeiser HH, Phillips DH, Stiborova M. Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. Cancer Lett. 2006;234:220–231. PubMed

Arlt VM, Stiborová M, Henderson CJ, Thiemann M, Frei E, Aimová D, Singhs R, da Costa GG, Schmitz OJ, Farmer PB, Wolf CR, Phillips DH. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis. 2008;29:656–665. PubMed

Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis. 2002b;17:265–277. PubMed

Arlt VM, Alunni-Perret M, Quatrehomme G, Ohayon P, Albano L, Gaid H, Michiels JF, Meyrier A, Cassuto E, Wiessler M, Schmeiser HH, Cosyns J-P. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int J Cancer. 2004;111:977–980. PubMed

Arlt VM, Stiborová M, vom Brocke J, Simoes ML, Lord GM, Nortier JL, Hollstein M, Phillips DH, Schmeiser HH. Aristolochic acid mutagenesis: molecular clues to the etiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogensis. 2007;28:2253–2261. PubMed

Arlt VM, Stiborova M, Henderson CJ, Osborne MR, Bieler CA, Frei E, Martinek V, Sopko B, Wolf CR, Schmeiser HH, Phillips DH. Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res. 2005;65:2644–2652. PubMed

Chan W, Cu L, Xu G, Cai Z. Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry, Rapid Commun. Mass Spectrom. 2006;20:1755–1760. PubMed

Chan W, Luo H-B, Zheng Y, Cheng Y-K, Cai Z. Investigation of the metabolism and reductive activation of carcinogenic aristolochic acid in rats. Drug Metab Dispos. 2007;35:866–874. PubMed

Cosyns JP. Aristolochic acid and “Chinese herbs nephropathy”: a review of the evidence to date. Drug Safety. 2003;26:33–48. PubMed

Dong H, Suzuki N, Torres MC, Bonala RR, Johnson F, Grollman AP, Shibutan S. Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab Dispos. 2006;34:1122–1127. PubMed

Gillerot G, Jadoul M, Arlt VM, van Ypersele de Strihou C, Schmeiser HH, But PHH, Bieler CA, Cosyns J-P. Aristolochic acid nephropathy in a Chinese patient: time to abandon the term “Chinese herbs nephropathy”? Am J Kidney Dis. 2001;38:E26. PubMed

Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky R, Goodenough AK, Rieger R, Vukelic M, Jelakovic B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sc USA. 2007;104:12129–12134. PubMed PMC

Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, Jelakovic B. Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat Med J. 2005;46:116–125. PubMed

IARC (International Agency for Research on Cancer) Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum. 2002;82 PubMed PMC

Ivic M. Etiology of endemic nephropathy. Lijec Vjesn. 1969;91:1273–1281. PubMed

Liu Z, Hergenhahn M, Schmeiser HH, Wogan GN, Hong A, Hollstein M. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Nat Acad Sc USA. 2004;101:2963–2968. PubMed PMC

Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, Schmeiser HH. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis. 2004;43:e11–17. PubMed

Meinl W, Pabel U, Osterloh-Quitroz H, Hengstler JG, Glatt H. Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int J Cancer. 2006;118:1090–1097. PubMed

Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petřin M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) N Engl J Med. 2000;342:1686–1692. PubMed

Nortier JL, Schmeiser HH, Martinez MCM, Arlt VM, Vervaet C, Garbar CH, Daelemans P, Vanherweghem JL. Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur with-out severe renal failure. Nephrol Dial Transplant. 2003;18:426–428. PubMed

Qi X, Cai Y, Gong L, Liu L, Chen F, Xiao Y, Wu X, Li Y, Xue X, Ren J. Role of mitochondrial permeability transition in human renal tubuar epithelial cell death induced by aristolochic acid. Toxicol Appl Pharmacol. 2007;222:105–110. PubMed

Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 1996;56:2025–2028. PubMed

Stefanovic V, Toncheva D, Atanasova S, Polenakovic M. Etiology of Balkan endemic nephropathy and associated urothelial cancer. Am J Nephrol. 2006;26:1–11. PubMed

Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudeček J, Phillips DH, Frei E. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol. 2008a;226:318–327. PubMed

Stiborová M, Frei E, Arlt VM, Schmeiser HH. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res. 2008b;658:55–67. PubMed

Stiborová M, Frei E, Breuer A, Bieler C A, Schmeiser HH. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. Exp Toxic Pathol. 1999;51:421–427. PubMed

Stiborová M, Frei E, Breuer A, Wiessler M, Schmeiser HH. Evidence for reductive activation of carcinogenic aristolochic acids by prostaglandin H synthase – 32P-postlabeling analysis of DNA adduct formation. Mutat Res. 2001a;493:149–160. PubMed

Stiborová M, Frei E, Wiessler M, Schmeiser HH. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochrome P450 1A1 and 1A2. Chem Res Toxicol. 2001c;14:1128–1137. PubMed

Stiborová M, Frei E, Schmeiser HH. Biotransformation enzymes in development of renal injury and urothelial cancer cause by aristolochic acid. Kidney Int. 2008c;73:1209–1211. PubMed

Stiborová M, Frei E, Sopko B, Wiessler M, Schmeiser HH. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis. 2002a;23:617–625. PubMed

Stiborová M, Frei E, Sopko B, Sopková K, Marková V, Laňková M, Kumstýřová T, Wiessler M, Schmeiser HH. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis. 2003;24:1695–1703. PubMed

Stiborová M, Frei E, Hodek P, Wiessler M, Schmeiser HH. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer. 2005a;113:189–197. PubMed

Stiborová M, Hájek M, Frei E, Schmeiser HH. Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH:cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy. Gen Physiol Biophys. 2001b;20:375–392. PubMed

Stiborová M, Patočka J, Frei E, Schmeiser HH. Biochemistry and toxicological aspects of etiology of Balkan endemic nephropathy. Chem Listy. 2005b;99:782–788.

Stiborová M, Sopko B, Hodek P, Frei E, Schmeiser HH, Hudeček J. The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. Cancer Lett. 2005c;229:193–204. PubMed

Tatu CA, Oren WH, Finkelman RB, Feder GL. The etiology of Balkan endemic nephropathy: still more questions than answers. Environ Health Perspect. 1998;106:689–700. PubMed PMC

Toncheva DI, von Ahsen N, Atanasova SY, Dimitrov TG, Armstrong VM, Oellerich M. Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. J Nephrol. 2004;17:384–389. PubMed

Toncheva D. Genetic studies in BEN and associated urothelial cancers. Coll. Antropol. 2006;30(1):34.

Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Valdervelde D, Verbeelen D, Vanhaelen-Fastre B, Vanhaelen M. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993;341:387–391. PubMed

Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. Identification of aristolochic acid in Chinese herbs. Lancet. 1994;343:174. PubMed

Xiao Y, Ge M, Xue X, Wang H, Wu X, Li L, Liu L, Qi X, Zhang Y, Li Y, Xie T, Gu J, Ren J. Detoxication role of hepatic cytochrome P450s in the kidney toxicity induced by aristolochic acid. Kidney Int. 2008;73:1231–1239. PubMed

DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer

Comparison of the oxidation of carcinogenic aristolochic acid I and II by microsomal cytochromes P450 in vitro: experimental and theoretical approaches